Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SRSF1 Antibodies:
anti-Mouse (Murine) SRSF1 Antibodies:
anti-Rat (Rattus) SRSF1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal SRSF1 Primary Antibody for ICC, IF - ABIN4353084
Brown, Dobrikov, Gromeier et al.: Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated ... in Journal of virology 2014
Show all 2 Pubmed References
Cow (Bovine) Polyclonal SRSF1 Primary Antibody for IHC, WB - ABIN2779013
Velazquez-Dones, Hagopian, Ma, Zhong, Zhou, Ghosh, Fu, Adams: Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. in The Journal of biological chemistry 2005
Show all 2 Pubmed References
DLP (show DMD Antibodies) and ASF1 are part of a predeposition complex, which is recruited by XNP (show ATRX Antibodies) and is necessary to prevent DNA exposure in the nucleus.
ASF1 cellular levels are tightly controlled by distinct pathways and provide a molecular mechanism for post-translational regulation of dASF1 and hASF1a (show ASF1A Antibodies) by TLK (show TLK2 Antibodies) kinases.
dASF1 has a direct role in modifying chromatin structure during DNA replication and this function of dASF1 is important for the processivity of the replication machinery.
Asf1 is directed via interactions with sequence-specific complexes to mediate silencing of specific target genes.
Histone chaperones ASF1 and NAP1 (show NAP1L1 Antibodies) differentially modulate removal of active histone marks by LID-RPD3 (show HDAC1 Antibodies) complexes during NOTCH (show NOTCH1 Antibodies) silencing.
high level of SF2, as a novel oncoprotein in RCC (show XRCC1 Antibodies), was significantly associated with poor survival in a large cohort of RCC (show XRCC1 Antibodies) specimens. Taken together, our study presents a road map for the prediction and validation of miR (show MLXIP Antibodies)-766-3p/SF2 axis and thus imparts a therapeutic way for further RCC (show XRCC1 Antibodies) progression.
The authors found that RNA recognition motif 1 (RRM1 (show RRM1 Antibodies)) in SRSF1 binds PP1 (show PPA1 Antibodies) and represses its catalytic function through an allosteric mechanism.
We present a joint atomistic molecular dynamics (MD) and experimental study of two RRM-containing proteins bound with their single-stranded target RNAs, namely the Fox-1 (show A2BP1 Antibodies) and SRSF1 complexes.The simulations predict unanticipated specific participation of Arg142 at the protein-RNA interface of the SRFS1 complex, which is subsequently confirmed by NMR and ITC measurements
Using NMR spectroscopy with two separately expressed domains of SRSF1, we showed that several residues in the RNA-binding motif 2 interact with the N-terminal region of the RS domain (RS1 (show RS1 Antibodies)).
Especially, in SRSF1 morphants, bone cartilage formation was reduced in the brain and Nkx-2.5 (show NKX2-5 Antibodies) expression was dramatically reduced in the heart of SRSF1 morphants. In addition, a dramatic reduction in functional chordin (show CHRD Antibodies) RNA in SRSF1 morphants was observed suggesting that chordin (show CHRD Antibodies) is one of the targets of SRSF1. Thus, we concluded that SRSF1 is an essential factor for pattern formation including heart, cartilage and germ lay
results strongly support SRSF1 as a prognostic biomarker in SCLC and provide a rationale for personalized therapy in SCLC
NSrp70 (show NSRP1 Antibodies) acts as a new molecular counterpart for alternative splicing of target RNA, counteracting SRSF1 and SRSF2 (show SRSF2 Antibodies) splicing activity.
we have identified for the first time a potential mechanism that involves the essential splicing factor (show SLU7 Antibodies) ASF/SF2 through which morphine regulates splicing specificity of the MOR (show OPRM1 Antibodies) encoding gene, OPRM1 (show OPRM1 Antibodies).
Global splicing analysis with RNA-seq revealed that exons carrying the hnRNP H (show HNRNPH1 Antibodies)-binding GGGGG motif are predisposed to be skipped compared to those carrying the SRSF1-binding GGAGG motif in both human and mouse brains.
We present experimental evidence that splicing factor (show SLU7 Antibodies) SRSF1, SRSF2 (show SRSF2 Antibodies), U2AF35 (show U2AF1 Antibodies), U2AF65 (show U2AF59 Antibodies) and KHSRP (show KHSRP Antibodies) expression levels in gastrointestinal tract (colon, gastric and pancreatic) tumors differ compare to healthy tissues and in cell lines
The expression levels of three splicing factors, ESRP1 (show ESRP1 Antibodies), PTB (show PTBP1 Antibodies) and SF2/ASF, are significantly altered during cardiac hypertrophy in mice.
RRP1B suppresses metastatic progression by altering the transcriptome through its interaction with splicing regulators such as SRSF1
Deletion of RRM1 (show RRM1 Antibodies) eliminated the splicing activity of SRSF1 and thus cellular transformation.
Specific effects on regulated splicing by SR proteins SRSF1 and SRSF2 (show SRSF2 Antibodies) depends on a complex set of relationships with multiple other SR proteins in mammalian genomes.
Treatment with IL-17 (show IL17A Antibodies) prolongs the half-life of chemokine (show CCL1 Antibodies) CXCL1 (show CXCL1 Antibodies) mRNA via the adaptor TRAF5 (show TRAF5 Antibodies) and the splicing-regulatory factor SF2 (ASF).
analysis of the miRNA-mediated interaction between leukemia/lymphoma-related factor (LRF (show ZBTB7A Antibodies)) and alternative splicing factor/splicing factor (show SLU7 Antibodies) 2 (ASF/SF2) affects cell senescence and apoptosis
Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 (show SMN1 Antibodies) causes spinal muscular atrophy in the absence of SMN1 (show SMN1 Antibodies)
Both hnRNP A1 (show HNRNPA1 Antibodies) and alternative splicing factor/splicing factor (show SLU7 Antibodies) 2 contents rose in adenomas and during injury-induced hyperplasia compared to control lungs
These results highlight the requirement of Sfrs1-mediated alternative splicing for the survival of retinal neurons, with sensitivity defined by the window of time in which the neuron was generated.
This gene encodes a member of the arginine/serine-rich splicing factor protein family, and functions in both constitutive and alternative pre-mRNA splicing. The protein binds to pre-mRNA transcripts and components of the spliceosome, and can either activate or repress splicing depending on the location of the pre-mRNA binding site. The protein's ability to activate splicing is regulated by phosphorylation and interactions with other splicing factor associated proteins. Multiple transcript variants encoding different isoforms have been found for this gene. In addition, a pseudogene of this gene has been found on chromosome 13.
, anti- silencing function 1
, anti-silencing factor
, splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor)
, SR splicing factor 1
, alternative-splicing factor 1
, pre-mRNA-splicing factor SF2, P33 subunit
, splicing factor 2
, splicing factor, arginine/serine-rich 1
, splicing factor arginine/serine-rich 1
, splicing factor, arginine/serine-rich 1B
, pre-mRNA-splicing factor SRp30a
, splicing factor, arginine/serine-rich 1 (ASF/SF2)
, serine/arginine-rich splicing factor 1B
, splicing factor, arginine/serine-rich 1b